secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001785530-22-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q3 2022 net loss of $11.9M; first patient dosed in WTX-124 Phase 1/1b trial
--------------------------------------------------------------------------------

- Net loss of $11.9M for Q3 2022 vs $13.8M in Q3 2021; cash and equivalents $140.5M as of Sept 30.
- First patient dosed in Phase 1/1b trial of WTX-124 (IL-2 INDUKINE) as monotherapy and in combination with KEYTRUDA; initial data expected Q4 2023.
- FDA cleared IND for WTX-330 (IL-12 conditionally activated molecule); Phase 1 study in immunotherapy-resistant tumors starting.
- Collaboration revenue from Jazz licensing agreement was $5.0M in Q3 2022 (none in prior year); R&D expenses $13.1M.
- Cash runway through at least Q2 2024, supported by existing cash, anticipated collaboration revenue, and term loan facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/0001785530-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/howl-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001785530-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer